Hellow guys, Welcome to my website, and you are watching ASCO 2023: highlights in non-small cell lung cancer. and this vIdeo is uploaded by VJOncology at 2023-06-08T02:23:55-07:00. We are pramote this video only for entertainment and educational perpose only. So, I hop you like our website.
| Name | ASCO 2023: highlights in non-small cell lung cancer |
| Video Uploader | Video From VJOncology |
| Upload Date | This Video Uploaded At 08-06-2023 05:23:55 |
| Video Discription | Joshua Sabari, MD, NYU Langone Health Perlmutter Cancer Center, New York, NY, gives an overview of influential lung cancer trials at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress, including overall survival findings from the Phase III ADAURA trial (NCT02511106), which assessed osimertinib in non-small cell lung cancer (NSCLC) in the adjuvant setting. Dr Sabari additionally highlights results from the ALINA trial (NCT03456076) of alectinib in NSCLC. This interview took place at ASCO 2023 Annual Congress in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved. |
| Category | Education |
| Tags | Speaker: Joshua Sabari | Institution: NYU Langone Health Perlmutter Cancer Center | Event: ASCO 2023 | Format: Interview | Subject: Non-Small Cell Lung Cancer | Subject: Lung Cancer | Field: Treatment | Field: Trial Updates | Trial: ADAURA | Trial: ALINA | Medicines: Osimertinib | Medicines: Alectinib | NCT03456076 | NCT02511106 | NSCLC |
